ArticleThe European respiratory journal2017
A standardised method for interpreting the association between mutations and phenotypic drug resistance in
Open access · bronzeAbstract read
In one paragraph
Article in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 5 pooled it
24.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 5 syntheses or guidelines pooled it, 328 citations in OpenAlex.
- Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis.The Lancet. Microbe · 2024Pooled it
- Genetic variants and their association with phenotypic resistance to bedaquiline inThe Lancet. Microbe · 2021Pooled it
- Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Pooled it
- Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019Guideline
- The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo.Scientific reports · 2020Trial
- Algorithmic Determinants of Performance Heterogeneity in Whole-Genome Sequencing-Based Prediction of Drug Resistance inMicroorganisms · 2026Review
- Article
- Operational considerations for implementing culture-free mycobacterial sequencing in routine laboratory settings.Journal of clinical microbiology · 2026Article
- Current Landscape of Molecular Diagnostic Tests and Emerging Tools for Tuberculosis and Drug Resistance.Diagnostics (Basel, Switzerland) · 2026Review
- Assessing fluoroquinolone resistance in Mycobacterium tuberculosis using nanopore sequencing: concordance with established diagnostic methods.Infection · 2026Article
- Point of care antimicrobial susceptibility testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- A cartridge-based assay for improved detection of multidrug-resistantJournal of clinical microbiology · 2026Article
- Global-scale population genetic analysis of Plasmodium falciparum identifies region-specific patterns of malaria parasite adaptation.Nature communications · 2026Article
- Artificial Intelligence for Tuberculosis Screening and Detection: From Evidence to Policy and Implementation.Diagnostics (Basel, Switzerland) · 2026Review
- Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDRMicrobiology spectrum · 2026Article
- Toward precision detection of pyrazinamide resistance: critical concentration assessment and rapid molecular method validation.Frontiers in microbiology · 2026Article
- Mutations inInfection and drug resistance · 2026Article
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction inFrontiers in microbiology · 2026Article
138 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors at 20 institutions in 15 countries.
Paolo MiottoEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy miotto.paolo@hsr.it.ORCID 0000-0003-4610-2427
Belay TessemaDepartment of Medical Microbiology, University of Gondar, Gondar, Ethiopia.
Elisa TaglianiEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Leonid ChindelevitchSchool of Computing Science, Simon Fraser University, Burnaby, BC, Canada.
Angela M StarksDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Claudia EmersonInstitute on Ethics & Policy for Innovation, Department of Philosophy, McMaster University, Hamilton, ON, Canada.
Debra HannaCritical Path Institute, Tucson, AZ, USA.
Peter S KimOffice of AIDS Research, National Institutes of Health, Rockville, MD, USA.
Richard LiwskiCritical Path Institute, Tucson, AZ, USA.
Matteo ZignolGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Christopher GilpinGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Stefan NiemannMolecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Borstel, Germany.
Claudia M DenkingerFoundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland.
Joy FlemingKey Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Robin M WarrenDST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Derrick CrookNuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
James PoseyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sebastien GagneuxSwiss Tropical and Public Health Institute, Basel, Switzerland.
Sven HoffnerMicrobiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Camilla RodriguesHinduja Hospital, Veer Savarkar Marg, Mumbai, India.
Iñaki ComasTuberculosis Genomics Unit, Biomedicine Institute of Valencia (IBV-CSIC), Valencia, Spain.
David M EngelthalerTranslational Genomics Research Institute, Flagstaff, AZ, USA.
Megan MurrayHarvard School of Public Health, Department of Epidemiology, Boston, MA, USA.
David AllandCenter for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, NJ, USA.
Leen RigoutsDepartment of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Christoph LangeDivision of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany.
Keertan DhedaLung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.
Rumina HasanDepartment of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
Uma Devi K RanganathanNational Institute for Research in Tuberculosis (ICMR), No 1, Chennai, India.
Ruth McNerneyDepartment of Medicine, Division of Pulmonology, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.
Matthew EzewudoCritical Path Institute, Tucson, AZ, USA.
Daniela M CirilloEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marco SchitoCritical Path Institute, Tucson, AZ, USA.
Claudio U KöserDepartment of Genetics, University of Cambridge, Cambridge, UK.
Timothy C RodwellFoundation for Innovative New Diagnostics, Campus Biotech, Geneva, Switzerland.
Critical Path Institute · USVita-Salute San Raffaele University · ITCenters for Disease Control and Prevention · USFIND · CHUniversity of Cape Town · ZAWorld Health Organization · CHAga Khan University · PKChinese Academy of Sciences · CNFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESGerman Center for Infection Research · DEHarvard University · USInstituut voor Tropische Geneeskunde · BEJohn Radcliffe Hospital · GBMcMaster University · CANational Institute of Research in Tuberculosis · INNational Institutes of Health · USP. D. Hinduja Hospital and Medical Research Centre · INPublic Health Agency of Sweden · SERutgers, The State University of New Jersey · USSimon Fraser University · CA
Funding
European Research Council 638553World Health Organization 001
Abstract
A clear understanding of the genetic basis of antibiotic resistance in
Indexed as
Data Interpretation, StatisticalAntitubercular AgentsBacterial ProteinsDNA, BacterialDrug Resistance, Multiple, BacterialGenotypeHumansMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPhenotypeSequence Analysis, DNASystematic Reviews as TopicTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsDNA, Bacterial
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.